b'INDUSTRY NEWSApellis Announces U.S. FDA Approval of EMPAVELI (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) May 14, 2021 EMPAVELI has the potential to improve the lives of patients with PNH by increasing hemoglobin and reducing blood transfusion requirements, said Olga Frankfurt, M.D., PEGASUS study investigator and associate professor in the department of medicine, division of hematology and oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Through my work as an investigator on the PEGASUS study, I was excited to see EMPAVELI providing broad control of PNH."Read Full ArticleHizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients April 29, 2021 This label update and data show that physicians can confidently adjust their patients subcutaneous immune globulin treatment, said Arie Katz, Senior Medical Director at CSL Behring. Providing consistency in a proven treatment can lessen some of the burden that patients living with CIDP may face.Hizentra is the most prescribed self-infused subcutaneous immune globulin (SCIg) treatment and the first and only SCIg treatment approved for CIDP, allowing CIDP patients the flexibility to self-infuse their immune globulin treatment at home. In 2020, CSL Behring introduced the first and only pre-filled syringes as a simple, convenient and ready-to-use option.Read Full Article7| KORU Q2 2021'